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Abstract
When patients need to take medicine, particu-
larly taking more than one kind of drug simul-
taneously, they should be alarmed that there
possibly exists drug-drug interaction. Interac-
tion between drugs may have a negative im-
pact on patients or even cause death. Gener-
ally, drugs that conflict with a specific drug
(or label drug) are usually described in its
drug label or package insert. Since more and
more new drug products come into the mar-
ket, it is difficult to collect such information
by manual. We take part in the Drug-Drug In-
teraction (DDI) Extraction from Drug Labels
challenge of Text Analysis Conference (TAC)
2018, choosing task1 and task2 to automati-
cally extract DDI related mentions and DDI
relations respectively. Instead of regard-
ing task1 as named entity recognition (NER)
task and regarding task2 as relation extrac-
tion (RE) task then solving it in a pipeline,
we propose a two step joint model to detect
DDI and it’s related mentions jointly. A se-
quence tagging system (CNN-GRU encoder-
decoder) finds precipitants first and search its
fine-grained Trigger and determine the DDI
for each precipitant in the second step. More-
over, a rule based model is built to determine
the sub-type for pharmacokinetic interation.
Our system achieved best result in both task1
and task2. F-measure reaches 0.46 in task1
and 0.40 in task2.
1 Introduction
A drug interaction is a situation in which a
substance (usually another drug) affects the
activity of a drug when both are adminis-
tered together. Drug-drug interactions can
lead to a variety of adverse events, and it
has been suggested that preventable adverse
events are the eighth leading cause of death
in the United States. Therefore, prescription
made up for patients should be cautious. Usu-
ally, precipitants with corresponding interac-
tion are listed in package insert for specific la-
bel drugs. However, researchers are difficult
to collect total DDI information from biomed-
ical literature manually since numerous drugs
are circulated in market. So methods that can
automatically extract information from drug
texts should be put forward as soon as pos-
sible.
With the development of machine learning,
some people have tried to apply ML methods
to DDI extraction. DDI Extraction 2011 task,
as well as DDI Extraction 2013 task, encour-
aged people to detect DDIs in literature with
information extraction (IE) methods. Some
work followed the DDI Extraction 2013 task
and obtained better result than the state-of-art
in 2013 task.
Different from DDI tasks in 2011 and 2013,
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Drug-Drug Interaction Extraction from Drug
Labels in TAC 2018 was divided into four
subtasks. We participated in task1 and task2,
which were proposed to extract mentions (pre-
cipitant, trigger, specificInteraction) and iden-
tify interaction types (pharmacokinetic, phar-
macodynamic, unspecified) in sentences re-
spectively. Tradition method to deal with
task1 and task2 is firstly using NER system
to find mentions in a sentence, then utiliz-
ing RE system to identify interaction of label
drug and precipitant. But in these two tasks,
we notice that the sentence in one drug la-
bel document share the same label drug and
the label drug is given. So we propose a
two-step joint model which only constructed
several NER system with the same architec-
ture, getting rid of traditional RE method to
obtain relation types of drug pair. We first
train a NER system to extract precipitants in
raw text. Then for each precipitant, we train
other two NER systems with identical struc-
ture to find its fine-grained trigger and speci-
ficInteraction if it exists. Fine-grained trigger
means trigger can be divided into three kinds:
pharmacokinetic trigger (PK-T), pharmacody-
namic trigger (PD-T) and unspecified (UN-T).
These triggers can indicate the relation types
directly.
The rest of this paper is organized as fol-
lows: we shortly depict two tasks that resem-
ble current tasks in section 2. We elaborate
model architecture and strategies we use in
section 3. In section 4, we describe data as
well as extra resources utilized in our model.
We describe the final submission and result in
section 5. In section 6, we draw our conclu-
sion.
2 Related Tasks
Beside DDI extraction task in TAC 2018, sim-
ilar DDI extraction tasks were proposed in
2011 and 2013. The DDIExtraction 2011
challenge task was relatively simple as it only
focused on judging whether if there contains
DDI information or not with given drug-drug
pairs in a sentence. The best performance was
achieved by the team WBI (Thomas et al.,
2011), system of which combines several ker-
nels and a case-based reasoning (CBR) using
a voting approach. In 2013, the challenge task
added a subtask of recognition and classifica-
tion of drug names, and it pursued the classifi-
cation of each drug-drug interaction according
to pre-defined types. The best result in NER
was achieved by the WBI team with a condi-
tional random field (CRF) (Rockta¨schel et al.,
2013), while best performance in RE was sub-
mitted by the team from FBK-irst (Chowd-
hury et al., 2013) with hybrid kernel based
RE approach. Both of subtasks in 2013 re-
semble task1 and task2 in this year, but there
are some differences in detail. The first sub-
task in 2013 need to classify drug names by
four types (drug, brand, group, drug-n), while
current task1 only requests to recognize pre-
cipitants. Present task1 seems to simplify the
recognition of drugs, but label drugs have to
be filtered. In addition, it is necessary to ex-
tract triggers and specificInteractions. In the
aspect of relation extraction, present task2 is
more challenging as its result relies on the
accuracy of task1s result, while the second
subtask in 2013 only identified DDI relations
based on given drug-drug pairs as drug entities
had been annotated.
3 System Architecture
We propose a two-step joint model to iden-
tify three kinds of mentions defined in Task 1
and three kinds of interactions defined in Task
2. An example is showed in Figure 1. We
notice that precipitant is the core attribute of
each interaction, i.e., each interaction contains
its corresponding precipitant which will inter-
act with label drug although the label drug
does not exist explicitly in this sentence. Each
drug-drug interaction we want to extract has
different information from other drug-drug in-
teractions. We try to understand drug-drug in-
teraction extraction task from human perspec-
tives. First, determine whether any drug ex-
ists in the given sentence including drug surro-
gates such as abbreviations and generic/trade
name equivalents. Second, determine whether
the identified drug is the label drug or not. If
its not the label drug, then determine whether
the trigger of drug-drug interaction exists in
the given sentence. If it does, we can extract
one drug-drug interaction and get its corre-
sponding attribute.
Two-step joint model consists of two se-
quence labeling systems. According to the
analysis above, the first step of two-step joint
model is to find the trigger location based on
the semantic information of given sentence
and the position features of label drug. The
second step is to construct some features by
using the precipitant found in the first step and
recognize the related trigger. Once the trigger
is not mentioned in the sentence, the precipi-
tant found in the first step will be discarded.
The triggers of PK interactions and Unspec-
ified interactions annotated by official stan-
dard guideline sufficiently indicate the exis-
tences of these two kinds of drug-drug inter-
actions while most of the triggers of PD dont,
for example, “increase of” is a trigger of PD
interaction but it does not provide enough ev-
idence of a drug-drug interaction. Therefore,
we regard the SpecificInteraction attribute of
PD interaction as the trigger word in the sec-
ond step. Another sequence labeling system
is applied to find the real trigger attributes of
PD interactions as Figure 1 shows. For one
precipitant, its related real trigger and Speci-
ficInteraction will be merged to generate final
result.
3.1 Construct Input Features
3.1.1 Input Features of First Step
In the first step, the sequence labeling sys-
tem utilizes two features. The first feature di-
vides each word into four types, UPPER (all
letters of the word are capitalized), UPPER-
FIRST (only the first letter of the word is cap-
italized), LOWER (all the letters of the word
are lowercase) and NUM-PUNC (represent-
ing the word as a number or a punctuation,
e.g. 86%). This feature can be regarded as an
extension of capitalization feature. The sec-
ond feature is the distance feature between la-
bel drug and the current word. The distance
is directly defined as the number of words be-
tween label drug and the current word. The
distance is mapped to the final coarse-grained
position features of label drug and it’s value
is calculated according to a predefined num-
ber of intervals, such as (5m, 5m+5) interval
maps the value between 5m and 5m+ 5 to m
as the eigenvalue input (m = 1, 2, ...). When
label drug does not exist in the text, the feature
value is uniformly set to 200.
3.1.2 Input Features of Second Step
The second step of two-step joint model is
to recognize the associated trigger based on
identified precipitant in the first step, thereby
determining the drug-drug interaction type
simultaneously. We construct features in
each time-step, including word embeddings,
coarse-grained position features of precipi-
tants and character embeddings.
3.2 Tagging Schema
Commonly, in named entity recognition sys-
tems, annotated data is encoded using BIO
tagging, where each word is assigned into
one of three labels: B means beginning, I
means inside, and O means outside of a con-
cept. However, BIO encoding is not suffi-
cient because mentions in DDI task are of-
Figure 1: An example of two-step joint model applying to a sentence
ten disjoint concepts with overlapping words
or discontinuous spans. For example, the sen-
tence “increase the blood pressure and heart
rate” contains two SpecificInteraction entities,
“increase the blood pressure” and “increase |
heart rate”. The entity phrase “increase | heart
rate” is a disjoint mention and has a shared
word “increase” with the other entity phrase
“increase the blood pressure”. To handle those
disjoint mentions, we apply an alternative la-
bel encoding schema called BIOHD, where
H means overlapping portions and D means
shared portions. BIOHD encoding label set
can be written as {H,D} × {B, I}⋃{O}.
Figure 2 shows an example of BIOHD label
encoding with semantic type and annotated
mentions.
Figure 2: Examples of BIOHD tagging
In the second step of two-step joint model,
we need to determine the type of the trigger
while finding the trigger to determine the cor-
responding drug-drug interaction type. Now
the encoding label set is further expanded to
{{H,D}×{B, I}⋃{O}}x{PK,PD,UN},
which is the Cartesian product of labels and
DDI categories. Figure 3 shows an example
of a sentence with further expanded encoding
label set.
Figure 3: Examples of fine-grained BIOHD
tagging
Since there are only three types of drug-
drug interactions, the number of labels is not
very large even if the interaction type is en-
coded into a label.
3.3 Sequence Labeling Model
In the two steps of the two-step joint model,
we used the same sequence labeling model to
learn the mapping from input features to label-
ing sequences. The model consists of an en-
coder based on convolutional neural networks
(CNN) and a decoder based on recurrent neu-
ral networks (RNN). The CNN decoder passes
the concatenated embedding result of all the
features of each time-step through three con-
volutional layers, and finally generates the
coding features of each step through ReLU
(Rectified Linear Unit) active layer. The RNN
decoder decodes the features generated by the
of each step into the label set by using the bidi-
rectional GRU (Gated Recurrent Unit) net-
work. The model is illustrated with Figure 4.
Figure 4: Sequential tagging model
3.4 Hyperparameter Setting
We tune the model using cross validation on
the available dataset and use grid search to de-
termine the optimal parameters. All hyperpa-
rameters are detailed in the Table 1.
3.5 PK Subtype Classification
We design a pharmacokinetic (PK) subtype
classification model to determine the subtype
of PK because PK interactions must be fur-
ther classified and coded according to an FDA
picklist based on DDI validation guideline.
PK interactions consist of 20 subtypes de-
pending on three factors, whether the trend
Parameter Setting
Early stopping number 10
Decoder output size 28
Encoder output size 400
Beam size 8
Encoder filter size 3
Dropout rate 0.25
Batch size 32
Table 1: Parameter Setting
is INCREASED or DECREASED, which PK
parameter (AUC, Cmax, half-life, LEVEL
and Tmax) is affected and whether the effect
is on the DRUG or CONCOMITANT DRUG.
For a certain PK interaction, its correspond-
ing sentence, trigger, precipitant, label drug
which is implicitly or explicitly described in
the sentence are fed into PK subtype classifi-
cation model.
Considering that the trigger word itself con-
tains enough information to predict the former
two factors, a dictionary-based method is used
to decide whether the trend is INCREASED
or DECREASED and which PK parameter is
affected. We collect trigger keywords from
training dataset and then build up two dictio-
naries respectively called trend dictionary and
parameter dictionary. Then match the triggers
with items in two dictionaries and predict the
former two factors. For instance, the trigger
phrase “reduces | plasma concentrations” con-
tains a trend keyword “reduces” and a parame-
ter keyword “concentrations”, which strongly
demonstrates that the trend of this PK inter-
action is DECREASED and the affected pa-
rameter concentrations belongs to LEVEL ac-
cording to official guideline.
As for the third factor, we apply a rule-
based method, compute distance differences
between drugs and trigger to decide whether
the effect is on the DRUG or CONCOMI-
TANT DRUG. In general, when the label drug
Figure 5: An example of predicting the PK subtype
is not mentioned explicitly in the text, we rea-
sonably predict that the effect is on the CON-
COMITANT DRUG. Otherwise, compare the
difference between label drug and trigger with
the difference between concomitant drug (i.e.
precipitant) and trigger and find the smaller
one. If the drug is label drug or its surrogate,
we decide the effect is on the DRUG. If the
drug is precipitant, we decide the effect is on
the CONCOMITANT DRUG.
Combining the above results of three fac-
tors, we can get the subtype for a certain PK
interaction and code it according to the FDA
picklist. There is an illustration of how we
predict PK subtype in Figure 5. Table 2 shows
some examples.
4 Data and Extra Resources
4.1 Data
After careful observation and analysis, there
are some problems in Training-22 dataset an-
notated in gold standard format, including
sample duplication, annotation incorrectness
and mention annotation inconsistency with of-
ficial validation guideline, especially trigger
annotations. To address the above issues,
we manually correct the mention annotations
which dont comply with guideline specifica-
tions. In addition, data augmentation is done
because the scale of Training-22 dataset is not
very large.
We transform NLM-180 dataset into
Training-22 format according to certain
rules, thus augmenting the dataset. There
are some differences between NLM-180
and Training-22 in annotation format. In
NLM-180, label drugs are explicitly an-
notated. On the contrary, in Training-22,
label drugs are not labeled explicitly in the
extracted drug-drug interactions and are
defined at the beginning of each document.
Thus, annotated label drugs are filtered out
during our transformation from NLM-180
Examples of PK triggers Trend keyword Parameter keyword Prediction
increases exposure increases exposure INCREASED LEVEL
elevated plasma concentrations elevated concentrations INCREASED LEVEL
decreases exposure decreases exposure DECREASED LEVEL
lower serum levels lower levels DECREASED LEVEL
increased Cmax increased Cmax INCREASED CMAX
Table 2: Examples of PK triggers matching with the trend dictionary and parameter dictionary.
Figure 6: Ensemble method to determine the best sequence
format to Training-22 format. Meanwhile, the
definition of trigger in NLM-180 is distinct
from that in Training-22, especially the
trigger of PD. In fact, the trigger of PD in
NLM-180 corresponds to SpecificInteraction
of PD in Training-22 and NLM-180 lacks
real trigger field corresponding to trigger of
PD in Training-22. Therefore, during the
transformation we manually add trigger field
for PD according to the guideline standard.
The previous related DDI datasets cant be
used as supplementary resources directly due
to the unique data format of this competition
task. Since the datasets provided by organiz-
ers are from DailyMed, we download some
free resources from DailyMed and preprocess
the raw texts. We annotate the data at sentence
level with reference to the official DDI vali-
dation guideline. We sample numerous doc-
uments but only sample several sentences in
one document to guarantee data diversity and
richness. We are not professional in medicine,
a highly specialized domain, so plenty of pos-
itive samples are possibly omitted and it is
inevitable that there are some annotation er-
rors which hardly affect our model neverthe-
less. The number of sentences we annotate is
approximately 1100 and we split it into two
equal amount parts annotated as HS-part1 and
HS-part2.
Table 3: F score for each submission in test1
submit1 submit2 submit3
task1 46.36 43.81 45.25
task2 40.46 36.67 40.90
4.2 Extra Resources
We used some extra resources during training
process, including PubMed, PubMed Central
(PMC) corpus, Google Word2vec tool to train
word vectors.
5 Final Submission
For submission, we divide the available
dataset into several parts and train the model
with Adadelta algorithm, adjusting the learn-
ing rate dynamically. Figure 6 illustrates
dataset partition results. we use the predict re-
sult of model1 and model2 as the first and sec-
ond submission. One of the partitions serves
as a validation set to determine the hyper-
parameters of the model. Beam search is
used as a trade-off of greedy search decoding
method and Viterbi decoding method during
the test time.
In the third version, we designed a sim-
ple sequence decoding ensemble algorithm to
integrate the prediction results of the above
three models. In this ensemble algorithm, let
S1,1 be the score of the best sequence MS1
which is predicted by the first model of the
above three models. Then we compute the
score of MS1 using the other two models and
the results are denoted as S1,2 and S1,3 respec-
tively. The final score of MS1 is S1 = S1,1 +
S1,2 + S1,3. Similarly, S2 and S3 are calcu-
lated. According to biggest score Si, the MSi
is the optimal sequence predicted by the three
models.
Table 3 and Table 4 show the performance
of our each submission. It shows that the
Training-22 is not in full accordance with DDI
Table 4: F score for each submission in test2
submit1 submit2 submit3
task1 46.69 43.48 45.66
task2 35.72 32.93 34.79
validation guideline and the system proves to
be effective as we get the highest F1-score in
both two tasks.
6 Conclusion
In this paper, we describe our participation in
DDI extraction task in TAC 2018. We choose
to take part in task1 and task2, which was
separately regarded as NER task and RE task
from traditional view. Instead, we propose a
two-step joint model to recognize mentions as
well as relations jointly and build a rule based
model to judge the PK subtype. The system
proves to be effective as we get the highest
F1-score in both two tasks.
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